Merit Medical Systems, Inc. (NASDAQ:MMSI) Shares Acquired by nVerses Capital LLC

nVerses Capital LLC raised its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 154.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,800 shares of the medical instruments supplier’s stock after buying an additional 1,700 shares during the quarter. nVerses Capital LLC’s holdings in Merit Medical Systems were worth $241,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Anfield Capital Management LLC acquired a new stake in shares of Merit Medical Systems during the second quarter worth $86,000. Fort Washington Investment Advisors Inc. OH lifted its holdings in Merit Medical Systems by 25.8% in the second quarter. Fort Washington Investment Advisors Inc. OH now owns 240,730 shares of the medical instruments supplier’s stock worth $20,691,000 after acquiring an additional 49,360 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in Merit Medical Systems by 80.6% in the second quarter. Crossmark Global Holdings Inc. now owns 8,031 shares of the medical instruments supplier’s stock valued at $690,000 after acquiring an additional 3,584 shares during the period. F M Investments LLC acquired a new stake in shares of Merit Medical Systems during the 2nd quarter worth approximately $12,550,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Merit Medical Systems by 7.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,171 shares of the medical instruments supplier’s stock worth $1,476,000 after purchasing an additional 1,182 shares during the last quarter. Institutional investors own 99.66% of the company’s stock.

Insider Buying and Selling

In related news, Director F. Ann Millner sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $85.00, for a total transaction of $1,062,500.00. Following the completion of the sale, the director now directly owns 32,391 shares in the company, valued at $2,753,235. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Merit Medical Systems news, COO Neil Peterson sold 7,500 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $81.85, for a total transaction of $613,875.00. Following the sale, the chief operating officer now owns 14,819 shares in the company, valued at approximately $1,212,935.15. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director F. Ann Millner sold 12,500 shares of the firm’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $85.00, for a total transaction of $1,062,500.00. Following the completion of the transaction, the director now owns 32,391 shares of the company’s stock, valued at $2,753,235. The disclosure for this sale can be found here. Insiders own 3.70% of the company’s stock.

Merit Medical Systems Stock Up 0.7 %

Shares of MMSI stock opened at $96.68 on Monday. Merit Medical Systems, Inc. has a 1 year low of $62.58 and a 1 year high of $96.99. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.64 and a current ratio of 6.24. The business’s fifty day moving average is $88.05 and its 200-day moving average is $81.20. The stock has a market cap of $5.63 billion, a PE ratio of 55.56, a price-to-earnings-growth ratio of 2.51 and a beta of 0.88.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.04. Merit Medical Systems had a return on equity of 15.29% and a net margin of 9.02%. The firm had revenue of $338.00 million for the quarter, compared to analyst estimates of $334.94 million. Equities analysts expect that Merit Medical Systems, Inc. will post 3.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Robert W. Baird started coverage on Merit Medical Systems in a research note on Friday, June 28th. They set an “outperform” rating and a $96.00 price objective for the company. Needham & Company LLC increased their price objective on shares of Merit Medical Systems from $94.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Bank of America boosted their target price on shares of Merit Medical Systems from $87.00 to $92.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Piper Sandler upped their target price on shares of Merit Medical Systems from $97.00 to $100.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, Barrington Research reaffirmed an “outperform” rating and set a $100.00 price target on shares of Merit Medical Systems in a report on Tuesday, July 16th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $98.20.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.